The serine protease inhibitor of Kazal-type 9 (SPINK9) is expressed in lichen simplex chronicus, actinic keratosis and squamous cell carcinoma

详细信息    查看全文

• 作者：Lisa Redelfs ; Jan Fischer ; Clemens Weber ; Zhihong Wu…
• 关键词：Protease ; Inhibitor ; Actinic keratosis ; Squamous cell carcinoma ; Kallikrein ; Desquamation
• 刊名：Archives of Dermatological Research
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：308
• 期：2
• 页码：133-137
• 全文大小：1,192 KB
• 参考文献：1.Borgono CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Diamandis EP (2007) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 282(6):3640–3652CrossRef PubMed
  2.Brattsand M, Stefansson K, Hubiche T, Nilsson SK, Egelrud T (2009) SPINK9: a selective, skin-specific kazal-type serine protease inhibitor. J Invest Dermatol 129(7):1656–1665CrossRef PubMed
  3.Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, Dubus P, Hovnanian A (2009) Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 206(5):1135–1147PubMedCentral CrossRef PubMed
  4.Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, Egelrud T, Simon M, Serre G (2004) Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 122(5):1235–1244CrossRef PubMed
  5.Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafe JL, Wilkinson J, Taieb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (2000) Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 25(2):141–142CrossRef PubMed
  6.Eissa A, Amodeo V, Smith CR, Diamandis EP (2011) Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem 286(1):687–706PubMedCentral CrossRef PubMed
  7.Fernandez-Figueras MT, Carrato C, Saenz X, Puig L, Musulen E, Ferrandiz C, Ariza A (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 29(5):991–997. doi:10.​1111/​jdv.​12848 CrossRef PubMed
  8.Hansson L, Backman A, Ny A, Edlund M, Ekholm E, Ekstrand HB, Tornell J, Wallbrandt P, Wennbo H, Egelrud T (2002) Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J Invest Dermatol 118(3):444–449CrossRef PubMed
  9.Kantyka T, Fischer J, Wu Z, Declercq W, Reiss K, Schroder JM, Meyer-Hoffert U (2011) Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6. Peptides 32(6):1187–1192. doi:10.​1016/​j.​peptides.​2011.​03.​009 CrossRef PubMed
  10.Komatsu N, Saijoh K, Toyama T, Ohka R, Otsuki N, Hussack G, Takehara K, Diamandis EP (2005) Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br J Dermatol 153(2):274–281CrossRef PubMed
  11.Komatsu N, Takata M, Otsuki N, Toyama T, Ohka R, Takehara K, Saijoh K (2003) Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 121(3):542–549CrossRef PubMed
  12.Magert HJ, Standker L, Kreutzmann P, Zucht HD, Reinecke M, Sommerhoff CP, Fritz H, Forssmann WG (1999) LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 274(31):21499–21502CrossRef PubMed
  13.Meyer-Hoffert U, Schroder JM (2011) Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 15(1):16–23. doi:10.​1038/​jidsymp.​2011.​2 CrossRef PubMed
  14.Meyer-Hoffert U, Wu Z, Kantyka T, Fischer J, Latendorf T, Hansmann B, Bartels J, He Y, Glaser R, Schroder JM (2010) Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. J Biol Chem 285(42):32174–32181PubMedCentral CrossRef PubMed
  15.Meyer-Hoffert U, Wu Z, Schroder JM (2009) Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS One 4(2):e4372. doi:10.​1371/​journal.​pone.​0004372 PubMedCentral CrossRef PubMed
  16.Simon M, Jonca N, Guerrin M, Haftek M, Bernard D, Caubet C, Egelrud T, Schmidt R, Serre G (2001) Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 276(23):20292–20299CrossRef PubMed
  
• 作者单位：Lisa Redelfs (1)
  Jan Fischer (1)
  Clemens Weber (1)
  Zhihong Wu (1) (2)
  Ulf Meyer-Hoffert (1)
  
  1. Department of Dermatology, University Clinic Schleswig-Holstein, Campus Kiel, Kiel, Germany
  2. Institute of Biochemistry and Cell Biology, Zhejiang University of Science and Technology, Hangzhou, 310023, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Dermatology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-069X

文摘

The serine protease inhibitor of Kazal-type (SPINK) 9 was reported to be exclusively expressed in palmoplantar skin. SPINK9 is a specific inhibitor of the serine protease kallikrein-related peptidase 5 (KLK5), which contributes to the desquamation process of the stratum corneum. Herein, we demonstrated that SPINK9 is also expressed in lichen simplex chronicus. Moreover, we observed expression of SPINK9 in 51 % of lesions of actinic keratosis and squamous cell carcinoma. In conclusion, we demonstrate that SPINK9 is not only expressed in healthy palmoplantar skin, but also in dermatologic disorders like lichen simplex chronicus, actinic keratosis and squamous cell carcinoma. Keywords Protease Inhibitor Actinic keratosis Squamous cell carcinoma Kallikrein Desquamation